Annexins as potential targets in ocular diseases

Rafael André da Silva1, Vinicius Moraes de Paiva Roda2, Luiz Philipe de Souza Ferreira3

  • 1Biosciences Graduate Program, Institute of Biosciences, Letters and Exact Sciences, Universidade Estadual Paulista (UNESP), São José do Rio Preto, SP 15054-000, Brazil.

Drug Discovery Today
|September 27, 2022
PubMed

Insights

Annexins (AnxAs) are key proteins in eye health, but their specific roles and locations in the visual system are unclear. This review explores AnxA distribution and function, offering insights for new eye treatments.

Area of Science:

  • Ophthalmology and Molecular Biology
  • Cellular Biology and Biochemistry

Background:

  • Annexins (AnxAs) are Ca2+/phospholipid-binding proteins implicated in various diseases.
  • While their presence in the visual system is known, their precise functions and cellular expression patterns in the eye remain largely uncharacterized.
  • AnxAs possess pro-resolving properties relevant to ocular tissue homeostasis.

Purpose of the Study:

  • To review the current understanding of Annexin A1-8 isoform distribution and function within the visual system.
  • To explore the roles of AnxAs in both normal and pathological ocular conditions.
  • To discuss potential ophthalmologic treatment strategies involving AnxA1 and its mimetic peptide Ac2-26.

Main Methods:

  • Literature review of studies on Annexin distribution and function in the visual system.
  • Analysis of research on AnxA roles in ocular diseases.
  • Synthesis of information regarding therapeutic applications of Annexin A1 and Ac2-26.

Main Results:

  • Annexin A1-8 isoforms exhibit diverse distribution patterns throughout the ocular tissues.
  • AnxAs are involved in regulating inflammatory, immune, and structural processes in the eye.
  • Evidence suggests AnxAs play significant roles in conditions like uveitis, glaucoma, and age-related macular degeneration.

Conclusions:

  • Annexins are critical for maintaining ocular tissue homeostasis and resolving inflammation.
  • Targeting Annexin A1, particularly with recombinant forms or peptides like Ac2-26, shows promise for novel ophthalmologic therapies.
  • Further research into AnxA functions in specific ocular cell types is warranted to optimize treatment strategies.